Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

Yıl 2024, Cilt: 50 Sayı: 3, 419 - 423, 12.01.2025

Yasin Kutlu , Ahmet Bilici , Ömer Ölmez , Jamshid Hamdard , Ebru Karcı , Özgür Açıkgöz

https://doi.org/10.32708/uutfd.1515582

Öz

Kliniğimizde 2016-2023 yılları arasında takip edilen erken evre küçük hücreli dışı akciğer kanseri (KHDAK) hastalarında neoadjuvan tedavilerin etkinliğini değerlendirmeyi amaçladık. İstanbul Medipol Üniversitesi Tıp Fakültesi Tıbbi Onkoloji kliniğinde tedavi gören erken evre KHDAK hastalarının kayıtları retrospektif olarak incelendi. Neoadjuvan kemoterapi, kemoimmünoterapi veya kemoradyoterapi sonrası opere edilen hastalar çalışmaya dahil edildi. Yaş, cinsiyet, sigara öyküsü, ECOG performans skoru, klinik ve patolojik evre, histolojik tip, neoadjuvan immünoterapi veya radyoterapi kullanımı ve PD-L1 düzeyleri gibi klinikopatolojik özellikler kaydedildi. Klinikopatolojik faktörler ile patolojik tam yanıt (pCR) arasındaki ilişki analiz edildi. Yaş ortalaması 64 (aralık: 51-71) olan on yedi hasta dahil edildi. Patolojik tam yanıt oranı %29.4 olarak bulundu. 24 aylık hastalıksız sağkalım oranı %85.7 idi ve hastalık ilişkili ölüm bildirilmedi. Eş zamanlı radyoterapi, daha yüksek pCR oranları ile anlamlı olarak ilişkili bulundu. Diğer klinikopatolojik faktörler arasında istatistiksel olarak anlamlı fark saptanmadı. Neoadjuvan kemoterapi, kemoimmünoterapi ve kemoradyoterapi, erken evre KHDAK'de yüksek pCR ve hastalıksız sağkalım oranları ile etkili tedavi seçenekleridir. Eş zamanlı radyoterapi tedavi etkinliğini artırabilir ve daha fazla araştırılmalıdır. Bu bulgular, erken evre KHDAK tedavisinde neoadjuvan yaklaşımların önemini desteklemektedir.

Anahtar Kelimeler

akciğer kanseri, neoadjuvan tedavi, immünoterapi

Effectiveness of Neoadjuvant Therapies in Early-Stage Non-Small Cell Lung Cancer: Single Center Experience

Öz

We aimed to evaluate the effectiveness of neoadjuvant therapies in early-stage non-small cell lung cancer (NSCLC) patients followed at our clinic between 2016 and 2023. A retrospective review was conducted on the records of early-stage NSCLC patients treated at İstanbul Medipol University School of Medicine, Department of Medical Oncology. Patients receiving neoadjuvant chemotherapy, chemoimmunotherapy, or chemoradiotherapy followed by surgery were included. Clinical and pathological characteristics were documented, including age, gender, smoking history, ECOG performance status, clinical and pathological staging, histological type, use of neoadjuvant immunotherapy or radiotherapy, and PD-L1 levels. The relationship between clinical-pathological factors and pathological complete response (pCR) was analyzed. Seventeen patients with a median age of 64 (range: 51-71) were included. The pCR rate was 29.4%. The 24-month disease-free survival rate was 85.7%, with no disease-related deaths reported. Concurrent radiotherapy was significantly associated with higher pCR rates. Other clinical-pathological factors did not show statistically significant differences between pCR and non-pCR groups. Neoadjuvant therapies, including chemotherapy, chemoimmunotherapy, and chemoradiotherapy, are effective in early-stage NSCLC, demonstrated by high pCR and disease-free survival rates. Concurrent radiotherapy may enhance treatment efficacy and warrants further investigation. These findings support the use of neoadjuvant approaches in managing early-stage NSCLC.

Anahtar Kelimeler

lung cancer, neoadjuvant therapy, immunotherapy

Kaynakça

• 1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
• 2.Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC).Transl Lung Cancer Res. 2013;2(5):403-410. doi:10.3978/j.issn.2218-6751.2013.07.01
• 3.Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242-249. doi:10.3978/j.issn.2218-6751.2013.12.05
• 4.Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93(6):1813-1821. doi:10.1016/j.athoracsur.2012.03.031
• 5.Gentzler RD, Riley DO, Martin LW. Striving toward ImprovedOutcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. Curr Oncol Rep. 2020;22(11):109. Published 2020 Aug 15. doi:10.1007/s11912-020-00969-w
• 6.NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-1571. doi:10.1016/S0140-6736(13)62159-5
• 7.Goldstraw P, Chansky K, Crowley J, et al. The IASLC LungCancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol.2016;11(1):39-51. doi:10.1016/j.jtho.2015.09.009
• 8.Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage IIInon-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e314S-e340S. doi:10.1378/chest.12-2360
• 9.Rosner S, Liu C, Forde PM, Hu C. Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy orChemoradiotherapy for NSCLC: A Meta-Analysis. JTO Clin Res Rep. 2022;3(9):100384. Published 2022 Jul 31. doi:10.1016/j.jtocrr.2022.100384
• 10.Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol.2014;15(1):e42-e50. doi:10.1016/S1470-2045(13)70334-6
• 11.Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413-1422. doi:10.1016/S1470-2045(20)30453-8
• 12.Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plusChemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170
• 13.Buderi SI, Shackcloth M, Woolley S. Does induction chemoradiotherapy increase survival in patients with Pancoast tumour?. Interact Cardiovasc Thorac Surg. 2016;23(5):821-825. doi:10.1093/icvts/ivw216
• 14.Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of SouthwestOncology Group Trial 9416 (Intergroup Trial 0160). J ClinOncol. 2007;25(3):313-318. doi:10.1200/JCO.2006.08.2826
• 15.Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial ofpreoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol. 2008;26(4):644-649. doi:10.1200/JCO.2007.14.1911
• 16.Provencio M, Nadal E, González-Larriba JL, et al.Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):504-513. doi:10.1056/NEJMoa2215530
• 17.Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10(5):621-633. doi:10.1001/jamaoncol.2024.0057
• 18.Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004;78(4):1200-1206. doi:10.1016/j.athoracsur.2004.04.085
• 19.Kawaguchi K, Yokoi K, Niwa H, et al. A prospective, multi-institutional phase II study of induction chemoradiotherapyfollowed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801). Lung Cancer. 2017;104:79-84. doi:10.1016/j.lungcan.2016.12.011